- Monday is likely to be rough for Atossa Genetics (ATOS).
- The shares fell 49% AH Friday, as the company announced the voluntary recall of the ForeCYTE Breast Health Test and the Mammary Aspiration Specimen Cytology Test.
- Although a new premarket application is expected by the end of October, CEO Steven Quay says "the government shutdown makes the timing of [a presubmission] meeting and the subsequent filing impossible to predict."
- ATOS did not say when the tests would go on sale again.
From other sites
at Benzinga.com (Feb 26, 2015)
at Benzinga.com (Dec 30, 2014)
at MarketWatch.com (Sep 24, 2014)
at MarketWatch.com (Sep 23, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs